Role of silibinin in the management of diabetes mellitus and its complications

[1]  M. Goodarzi,et al.  Silymarin prevents lipid accumulation in the liver of rats with type 2 diabetes via sirtuin1 and SREBP-1c , 2018, Journal of basic and clinical physiology and pharmacology.

[2]  J. Karimi,et al.  Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  T. El-Elimat,et al.  Silymarin Ameliorates Diabetes-Induced Proangiogenic Response in Brain Endothelial Cells through a GSK-3β Inhibition-Induced Reduction of VEGF Release , 2017, Journal of diabetes research.

[4]  Xiao-zhou Ying,et al.  The protective effects of silibinin in the treatment of streptozotocin-induced diabetic osteoporosis in rats. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  C. Palmeira,et al.  Diabetic Cardiomyopathy: Focus on Oxidative Stress, Mitochondrial Dysfunction and Inflammation , 2017 .

[6]  K. Nave,et al.  New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain , 2017, Neuron.

[7]  R. Mohtashami,et al.  Silymarin, Olibanum, and Nettle, A Mixed Herbal Formulation in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial , 2017, Journal of evidence-based complementary & alternative medicine.

[8]  A. Acco,et al.  Effects of Silymarin on Diabetes Mellitus Complications: A Review , 2017, Phytotherapy research : PTR.

[9]  Qiang Zhang,et al.  The impairment of glucose-stimulated insulin secretion in pancreatic β-cells caused by prolonged glucotoxicity and lipotoxicity is associated with elevated adaptive antioxidant response. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[10]  S. Hu,et al.  High-glucose environment disturbs the physiologic functions of keratinocytes: Focusing on diabetic wound healing. , 2016, Journal of dermatological science.

[11]  S. Pattanayak,et al.  Wound Healing Activity of Silibinin in Mice , 2016, Pharmacognosy research.

[12]  A. Tahrani,et al.  Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus , 2016, Nature Reviews Endocrinology.

[13]  I. El-Sherbiny,et al.  A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes. , 2016, Nanomedicine.

[14]  M. A. Martín,et al.  Protective Effect of Silybum marianum and Silibinin on Endothelial Cells Submitted to High Glucose Concentration , 2016, Planta Medica.

[15]  Angelos Liontos,et al.  Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise , 2016, Hepatology International.

[16]  A. Covic,et al.  Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2016, Journal of diabetes research.

[17]  T. P. Davis,et al.  Pancreatic β-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide Species , 2016, Scientific Reports.

[18]  G. Li Volti,et al.  Silibinin Regulates Lipid Metabolism and Differentiation in Functional Human Adipocytes , 2016, Front. Pharmacol..

[19]  Yue Shen,et al.  Silibinin alleviates high glucose-suppressed osteogenic differentiation of human bone marrow stromal cells via antioxidant effect and PI3K/Akt signaling. , 2015, European journal of pharmacology.

[20]  Yujeong Lee,et al.  Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization , 2015, Journal of neuroscience research.

[21]  M. Ulbig,et al.  Diabetic retinopathy - ocular complications of diabetes mellitus. , 2015, World journal of diabetes.

[22]  R. Somani,et al.  Silibinin, a bioactive flavanone, prevents the progression of early diabetic nephropathy in experimental type-2 diabetic rats , 2015 .

[23]  Y. Ding,et al.  Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition , 2015, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[24]  M. Asghari-Jafarabadi,et al.  Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial. , 2015, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[25]  E. Y. Kim,et al.  Blockade of lipid accumulation by silibinin in adipocytes and zebrafish. , 2015, Chemico-biological interactions.

[26]  Ke Chen,et al.  [Protective effect of silibinin on islet β cells in C57BL/6J mice fed a highfat diet]. , 2015, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[27]  Dan Ziegler,et al.  From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. , 2015, Journal of diabetes and its complications.

[28]  M. Tuorkey,et al.  Cytoprotective effect of silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. , 2015, Biomedical and environmental sciences : BES.

[29]  Yi Ding,et al.  Silibinin Prevents Autophagic Cell Death upon Oxidative Stress in Cortical Neurons and Cerebral Ischemia-Reperfusion Injury , 2016, Molecular Neurobiology.

[30]  S. Radford,et al.  Screening and classifying small molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry , 2014, Nature Chemistry.

[31]  S. Rani,et al.  Apoptosis of beta cells in diabetes mellitus. , 2014, DNA and cell biology.

[32]  H. Tian,et al.  Silybin reduces obliterated retinal capillaries in experimental diabetic retinopathy in rats. , 2014, European journal of pharmacology.

[33]  F. Wang,et al.  Silibinin protects β cells from glucotoxicity through regulation of the Insig-1/SREBP-1c pathway. , 2014, International journal of molecular medicine.

[34]  D. Scott,et al.  The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet β cells , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  A. Mukherjee,et al.  Engineered Silybin Nanoparticles Educe Efficient Control in Experimental Diabetes , 2014, PloS one.

[36]  M. Amiri,et al.  Beyond the liver protective efficacy of silymarin; bright renoprotective effect on diabetic kidney disease , 2014, Journal of nephropharmacology.

[37]  A. Klip,et al.  Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation. , 2014, American journal of physiology. Cell physiology.

[38]  Huazi Xu,et al.  Silibinin promotes osteoblast differentiation of human bone marrow stromal cells via bone morphogenetic protein signaling. , 2013, European journal of pharmacology.

[39]  A. Schmidt,et al.  Silibinin as a potential therapeutic for sulfur mustard injuries. , 2013, Chemico-biological interactions.

[40]  C. Ghelardini,et al.  Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy? , 2013, Free radical biology & medicine.

[41]  M. Tabandeh,et al.  Silibinin Regulates Matrix Metalloproteinase 3 (Stromelysine1) Gene Expression, Hexoseamines and Collagen Production During Rat Skin Wound Healing , 2013, Phytotherapy research : PTR.

[42]  A. Dey,et al.  The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. , 2013, Food & function.

[43]  M. Kwon,et al.  Low glibenclamide concentrations affect endoplasmic reticulum stress in INS-1 cells under glucotoxic or glucolipotoxic conditions , 2013, The Korean journal of internal medicine.

[44]  S. Chiu,et al.  Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology, and Potential Application of Selected Plants and Compounds , 2013, Evidence-based complementary and alternative medicine : eCAM.

[45]  Xiang Gao,et al.  Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver , 2013, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[46]  I. Tentes,et al.  Silibinin protects H9c2 cardiac cells from oxidative stress and inhibits phenylephrine-induced hypertrophy: potential mechanisms. , 2013, The Journal of nutritional biochemistry.

[47]  C. Lin,et al.  Silibinin inhibits VEGF secretion and age‐related macular degeneration in a hypoxia‐dependent manner through the PI‐3 kinase/Akt/mTOR pathway , 2013, British journal of pharmacology.

[48]  E. Hackett,et al.  Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. , 2013, Journal of veterinary internal medicine.

[49]  U. Narayanan,et al.  Chronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activity , 2013, BMC Cell Biology.

[50]  Chaodong Wu,et al.  Glycolysis in the control of blood glucose homeostasis , 2012 .

[51]  G. Li Volti,et al.  Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. , 2012, Translational research : the journal of laboratory and clinical medicine.

[52]  Keduo Qian,et al.  Recent discovery of plant-derived anti-diabetic natural products. , 2012, Natural product reports.

[53]  T. Ikejima,et al.  In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of sirt-1 expression and autophagy in pancreatic β-cell , 2012, Journal of Asian natural products research.

[54]  F. Bucchieri,et al.  Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[55]  Hong Chen,et al.  Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. , 2012, Biochemical and biophysical research communications.

[56]  C. Ghelardini,et al.  Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. , 2012, The journal of pain : official journal of the American Pain Society.

[57]  A. Bracht,et al.  Metabolic effects of silibinin in the rat liver. , 2012, Chemico-biological interactions.

[58]  P. Bosco,et al.  Neuroprotective effect of silibinin in diabetic mice , 2011, Neuroscience Letters.

[59]  Ke Chen,et al.  Overexpression of Insig-1 protects β cell against glucolipotoxicity via SREBP-1c , 2011, Journal of Biomedical Science.

[60]  G. Li Volti,et al.  CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice , 2022 .

[61]  W. Stremmel,et al.  Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins , 2011, Journal of cellular biochemistry.

[62]  Y. Ahn,et al.  Role of resveratrol in FOXO1-mediated gluconeogenic gene expression in the liver. , 2010, Biochemical and biophysical research communications.

[63]  A. Floreani,et al.  S1839 Effect of Silybin in Patients With Chronic Hepatitis: Preliminary Results of a Multicentre Randomized Controlled Trial vs Placebo , 2010 .

[64]  F. Bellanti,et al.  A Silybin-Phospholipid Complex Prevents Mitochondrial Dysfunction in a Rodent Model of Nonalcoholic Steatohepatitis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[65]  J. Chun,et al.  Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells. , 2010, Biochemical and biophysical research communications.

[66]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[67]  Jin-woo Park,et al.  Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway. , 2009, International journal of molecular medicine.

[68]  T. Anwer,et al.  Silymarin, a flavonoid antioxidant, protects streptozotocin-induced lipid peroxidation and β-Cell damage in rat pancreas , 2008 .

[69]  X. Leverve,et al.  Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. , 2008, Life sciences.

[70]  A. K. Cardozo,et al.  Mediators and mechanisms of pancreatic beta-cell death in type 1 diabetes. , 2008, Arquivos brasileiros de endocrinologia e metabologia.

[71]  S. Lenzen,et al.  The mechanisms of alloxan- and streptozotocin-induced diabetes , 2008, Diabetologia.

[72]  X. Leverve,et al.  The Flavonoid Silibinin Decreases Glucose-6-Phosphate Hydrolysis in Perifused Rat Hepatocytes by an Inhibitory Effect on Glucose-6-Phosphatase , 2007, Cellular Physiology and Biochemistry.

[73]  S. Chakrabarti,et al.  Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. , 2006, Pharmacology & therapeutics.

[74]  G. Muscat,et al.  Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. , 2005, The international journal of biochemistry & cell biology.

[75]  M. Permutt,et al.  Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. , 2005, Cell metabolism.

[76]  Jan Nedergaard,et al.  Brown adipose tissue: function and physiological significance. , 2004, Physiological reviews.

[77]  C. Kahn,et al.  Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. , 2003, The Journal of clinical investigation.

[78]  S. Ansorge,et al.  Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. , 2002, Free radical biology & medicine.

[79]  A. Astrup,et al.  Redefining Type 2 diabetes: ‘Diabesity’ or ‘Obesity Dependent Diabetes Mellitus’? , 2000, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[80]  A. Bracht,et al.  Glucose release by the liver under conditions of reduced activity of glucose 6-phosphatase. , 1987, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.